Amgen develops Myeloma blood cancer drug that outperforms rival Velcade in study

March 2, 2015 4:45 PM

13 0

Amgen, Inc. is forging forward with its Kyprolis cancer therapy, which according to an interim analysis enabled patients with relapsed multiple myeloma live twice as long before their blood cancer worsened. The company states that the drug performed much better than rival drug Velcade in a study.

Kyprolis was at the center of Amgen, Inc’s approximately $10 billion acquisition of Onyx Pharmaceutical in 2013 having generated $331 million in sales. Velcade, on the other hand, a drug from Takeda and Johnson & Johnson generated a total of 3 billion in sales last year.

Read more

To category page